Endo International | ENDP - Les Charges D'Exploitation



Les Charges D'Exploitation Changement Date
AbbVie USD 10.27B 1000K 2026-06
Amarin USD 51.48M 113K 2025-12
ANI Pharmaceuticals USD 597.21M 34.91M 2026-06
Bristol-Myers Squibb USD 22.32B 2.25B 2026-06
Coherus Biosciences USD 51.83M 2.48M 2025-12
Eli Lilly USD 10.52B 496M 2026-06
Heron Therapeutics USD 40.55M 1.46M 2025-12
Hikma Pharmaceutical USD 1.34B 702M 2025-12
Ligand Pharmaceuticals USD 55.1M 20.75M 2026-06
Merck USD 15.77B 2.4B 2026-06
Novartis USD 10.2B 912M 2026-06
Pacira USD 180.54M 7.79M 2026-06
Perrigo USD 290.5M 645.1M 2026-06
Pfizer USD 85.19B 4.91B 2026-06
Phibro Animal Health USD 361.83M 29.47M 2026-03
Supernus Pharmaceuticals USD 1.03B 45.58M 2026-06
Takeda JPY 1.02T 89.68B 2026-06
Teva Pharmaceutical Industries USD 3.92B 691M 2026-06
Xeris Pharmaceuticals USD 75.21M 6.18M 2026-03
Zoetis USD 3.15B 85M 2026-06